Last week, members of the European-funded RBDCOV project met at the Representation of the European Commission in Barcelona to hold the project’s final meeting. During the meeting, the developments and results achieved during this five-year project were discussed.
Asphalion experts Montse de Castellarnau and Montse Domingo attended the meeting, where they presented the final results of the Work Package 6 (WP6), focused on regulatory recommendations and strategic guidance for the vaccine. As the Marketing Authorisation Application (MAA) was already under preparation, the strategy recommendations were non-typical and referred to emerging and important regulatory procedural aspects related to activities in parallel to the MAA and/or afterwards.
The RBDCOV project has been a unique and excellent opportunity to develop the Bimervax® vaccine in greater for two very different populations: immunocompromised and pediatrics. Moreover, it has allowed for a deeper understanding of the vaccine’s mechanism of action.
This project has been very challenging because it started during the Covid-19 pandemic, making it challenging to coordinate all the different Asphalion teams that were involved in the development of the best regulatory strategy in a fast way.
We are very proud to have contributed to this important advancement.
Check out more about the project on the RBDCOV WEBSITE.
